Silicon Valley luminaries, led by Apple alumnus
and NeXT Computer co-founder Rich Page, to support the company’s
technology development, data and analytics, and consumer engagement
strategy
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a
diversified commercial-stage medical technology company today
announced that its majority-owned digital health subsidiary Veris
Health (“Veris”) has launched a world-class technology advisory
board consisting of Silicon Valley luminaries with broad expertise
in software development, hardware engineering, data and analytics,
machine learning, and consumer engagement. Silicon Valley pioneer
Rich Page, an early Apple alumnus who co-founded NeXT Computer with
Steve Jobs, will serve as chair. The advisory board held its
inaugural meeting earlier this week.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220310005522/en/
“We could not be more pleased to welcome this prominent group of
technology visionaries and pioneers to the Veris team,” said Sunny
M. Webb, Veris’ Chief Technology Officer and PAVmed’s VP, Data
& Analytics. “We believe the collective wisdom and experience
of our technology advisory board will elevate Veris products and
significantly enhance their clinical and commercial impact.”
“We look forward to tapping into this wisdom and experience to
help us incorporate state-of-the-art technology, including machine
learning, artificial intelligence, modern consumer engagement
methodologies, and data science, into our Veris platform to enhance
cancer care worldwide,” said Dr. James D. Mitchell, M.D., Veris’
Chief Medical Officer, and PAVmed’s VP, Digital Health.
“I have spent my career focused on transformational technologies
and building successful companies,” said Mr. Page. “I am excited to
join this innovative medical technology company with a clear
mission to improve cancer care using cutting-edge technologies. I
look forward to working with Dr. Aklog, Veris’ strong management
team, and my esteemed technology advisory board colleagues.
Together we have a unique opportunity to execute this important
mission.”
The Veris Health Technology Advisory Board
Rich Page
Mr. Page is an alumnus of Apple Inc. and
was one of the first four Apple Fellows. In the early days at
Apple, he prototyped some of the first Macintosh computers. He
later served as Vice President of Hardware Engineering, and
co-founder along with Steve Jobs, at NeXT Computer, Inc. Mr. Page
has also performed pioneering work at prominent technology
companies such as Hewlett Packard and Fairchild Semiconductor, and
founded and led Sierra Research & Technology, which was
acquired by TDK Semiconductor
Tushara Canekeratne
Ms. Canekeratne is a global technology
leader and entrepreneur with extensive experience in the
information technology industry with an emphasis on enterprise
technology, as well as scaling and growing global companies. She
founded and has led Nadastra, Inc., a knowledge-driven global
service company, since its inception. She previously co-founded
multiple technology companies, including Virtusa Corp., a
multi-billion-dollar information technology services company
targeting large enterprises and software vendors, and INSCI Corp.,
a leading provider of enterprise content management solutions. She
is an active early-stage venture investor and has served on the
board of directors or as an advisor to numerous companies,
including in the healthcare sector.
Namrata Gantra
Ms. Gantra is VP of Engineering at
multi-billion-dollar e-commerce giant Thrasio Inc. She previously
served as founder & CEO of Storepath Inc., an AI-based
e-commerce platform, which was later acquired by Thrasio. Ms.
Gantra has also held leadership roles at multiple leading
technology companies including Coinbase, Stockpile, Facebook,
Lambda School, PayPal, and Microsoft. She is a contributing
participant in the Forbes Technology Council.
Tatsiana Maskalevich
Ms. Maskalevich is the Director of Data
Science at Shopify Inc., a leading multinational e-commerce company
and platform. She previously spent years building state-of-the-art
recommender systems, including end-to-end solutions for
human-in-the-loop problems as Director of Data Science at Stitch
Fix Inc. (Nasdaq: SFIX), a leading multi-billion-dollar algorithm
and data science driven personal styling service company. She has
been a fixture in the Silicon Valley data science community at
multiple companies over the past decades.
Goku Mohandas
Mr. Mohandas is the founder of MadeWithML,
a community of 35K+ members focused on responsibly delivering value
with machine learning (ML). Previously, he led the ML team at
Ciitizen Corp., an Andreeessen Horowitz-backed consumer healthcare
technology startup using ML in the oncology space, which was
subsequently acquired by Invitae (NYSE: NVTA). He worked at Apple
Inc. on natural language processing as well as AI strategy and
development. Mr. Mohandas cofounded HotSpot, a successful
technology startup which developed a machine learning-based
rideshare app and performed research on nanotechnology for
regenerative medicine at John Hopkins School of Medicine. His
current focus is on intersection of health and machine learning,
while focusing on the data-centric aspects of machine learning
operations.
Veris, a majority-owned subsidiary of PAVmed, acquired Oncodisc
Inc., a digital health company with groundbreaking tools to improve
personalized cancer care in May 2021. Veris is developing a remote
cancer care platform that integrates an intelligent implantable
vascular access port with physiologic sensing, software with
symptom reporting and telehealth functions, and advanced data
analytics. Today’s aggressive outpatient cancer treatments,
including immunotherapy and chemotherapy, leave patients
unmonitored and at risk of serious, avoidable complications,
leading to high rates of hospitalization, poor patient quality of
life, and increasing health system costs. The Veris technology is
designed to allow oncologists to detect early signs of common
cancer-related complications, provide longitudinal trends of
physiologic and clinical data, offer data-driven risk management
tools for precision oncology, and incorporate additional prospects
for substantial value-creation through data monetization and
biotherapeutic clinical trial support. The technology contains
biologic sensors capable of generating continuous data on key
physiologic parameters known to predict adverse outcomes in cancer
patients undergoing treatment. Wireless communication to the
patient’s smartphone and its cloud-based digital healthcare
platform will deliver actionable real time data to patients and
physicians efficiently and effectively. Veris is targeting
commercial launch of the remote digital healthcare platform for
H2-2022.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its major subsidiary, Lucid Diagnostics Inc.
(Nasdaq: LUCD), markets the EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device—the first and only
commercial tools for widespread early detection of esophageal
precancer to prevent esophageal cancer deaths. Another major
subsidiary, Veris Health Inc., is a digital health company
developing the first intelligent implantable vascular access port
with biologic sensors and wireless communication to improve
personalized cancer care through remote patient monitoring.
PAVmed’s CarpX® Minimally Invasive Device for Carpal Tunnel
Syndrome is currently in limited commercial release. The product
pipeline also includes the EsoCure™ Esophageal Ablation Device with
Caldus™ Technology, which complements EsoGuard and EsoCheck, the
NextFlo™ Intravenous Infusion Set, the PortIO™ Implantable
Intraosseous Vascular Access Device, novel pediatric ear tubes,
mechanical circulatory support technology and glucose monitoring.
For more information, please visit www.pavmed.com, follow us on
Twitter, connect with us on LinkedIn, and watch our videos on
YouTube. For more information on our majority owned subsidiary,
Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid
on Twitter, and connect with Lucid on LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed’s management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of PAVmed’s common stock; PAVmed’s Series W and Series Z
warrants; general economic and market conditions; the uncertainties
inherent in research and development, including the cost and time
required to advance PAVmed’s products to regulatory submission;
whether regulatory authorities will be satisfied with the design of
and results from PAVmed’s clinical and preclinical studies; whether
and when PAVmed’s products are cleared by regulatory authorities;
market acceptance of PAVmed’s and products once cleared and
commercialized; PAVmed’s ability to raise additional funding as
needed; and other competitive developments. In addition, PAVmed has
been monitoring the COVID-19 pandemic and the pandemic’s impact on
PAVmed’s businesses. PAVmed expects the significance of the
COVID-19 pandemic, including the extent of its effect on its
financial and operational results, to be dictated by, among other
things, the success of efforts to contain the pandemic and the
impact of such efforts on PAVmed’s businesses. These factors are
difficult or impossible to predict accurately and many of them are
beyond PAVmed’s control. In addition, new risks and uncertainties
may arise from time to time and are difficult to predict. For a
further list and description of these and other important risks and
uncertainties that may affect PAVmed’s future operations, see Part
I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report
on Form 10-K filed with the Securities and Exchange Commission, as
the same may be updated in Part II, Item 1A, “Risk Factors” in any
Quarterly Report on Form 10-Q filed by PAVmed after its most recent
Annual Report filed with the Securities and Exchange Commission.
PAVmed disclaims any intention or obligation to publicly update or
revise any forward-looking statement to reflect any change in its
expectations or in events, conditions, or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220310005522/en/
Investors Adrian K. Miller PAVmed
Inc. AKM@PAVmed.com
Media Shani Lewis
LaVoieHealthScience (609) 516-5761
PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Sep 2023 to Sep 2024